Scotland approves new treatment option for multiple myeloma patients - PharmaTimes Blenrep combination offers improved survival for those ineligible for lenalidomide

#Haematology #Oncology #Scotland #NHSScotland #multiplemyeloma #GSK #Blenrep #belantamabmafodotin #Blenrepcombination #lenalidomide #ScottishMedicinesConsortium #SMC #bortezomibanddexamethasone #BVd #SMCrecommendation #phase3data #DREAMM7study #progressionfreesurvival
zurl.co/ydmDa

New treatment option for endometriosis approved in Scotland - PharmaTimes Linzagolix with add-back Therapy accepted for use within NHS Scotland

#NHSScotland #endometriosis #womenshealth #Gynaecology #Linzagolix #ScottishMedicinesConsortium #SMC #UK #NICE #England #Wales #NorthernIreland #endometriosismanagement #Theramex #SMCapproval #EndometriosisUK
pharmatimes.com/news/new-tre...

Scotland approves zanubrutinib for relapsed mantle cell lymphoma - PharmaTimes New treatment option now available across all UK nations

#NHSScotland #ScottishMedicinesConsortium #Haematology #BeOneMedicinesUK #BeOne #SMC #SMCrecommendation #zanubrutinib #BRUKINSA #relapsedmantlecelllymphoma #MCL #MCLpatients #refractorymantlecelllymphoma #nonHodgkinlymphoma #LymphomaAction #BeatsonWestofScotlandCancerCentre
zurl.co/lk0uJ

Eladynos recommended for osteoporosis treatment in Scottish NHS - PharmaTimes SMC approval provides option for postmenopausal women at risk of fractures

#NHSScotland #Scotland #osteoporosis #Rheumatology #Eladynos #abaloparatide #osteoporosistreatment #SMCapproval #SMCdecision #ScottishMedicinesConsortium #Theramex #NHS #fracturerelateddeaths #osteoporoticfractures #NHSspending #anabolictherapy #newboneformation
pharmatimes.com/news/eladyno...

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE The life-long condition affects approximately 1,900 people in Scotland

#hepatology #gastroenterology #Ipsen #Iqirvo #elafibranor #SMC #ScottishMedicinesConsortium #SMCapprovel #liverdisease #primarybiliarycholangitis #Scotland #NHSScotland #rarecholestaticliverdisease #NICE #NICErecommended #PBCpatients #ELATIVEtrial #cholestasis
pmlive.com/ipsens-iqirv...

SMC approves bimekizumab for hidradenitis suppurativa treatment - PharmaTimes The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not

#dermatology #immunology #UCB #SMC #SMCapprovel #bimekizumab #hidradenitissuppurativa #HS #hidradenitissuppurativatreatment #ScottishMedicinesConsortium #NHSScotland #HSpatients #phase3clinicaltrial #BEHEARDI #BEHEARDII #clincialstudies #patientoutcomes
pharmatimes.com/news/smc-app...

Pfizer's Talzenna therapy accepted for use within NHS Scotland - PharmaTimes Scottish Medicines Consortium approves new option for mCRPC patients

#prostatecancer #Pfizer #Talzenna #talazoparib #Talzennatherapy #NHSScotland #ScottishMedicinesConsortium #SMCapprovel #mCRPCpatients #metastaticcastrationresistantprostatecancer #mCRPC #polyADPribosepolymeraseinhibitor #PARPinhibitor #metastaticprostatecancer
pharmatimes.com/news/pfizers...

Libtayo available in Scotland for cervical cancer patients - PharmaTimes New immunotherapy offers hope for recurrent cervical cancer

#oncology #womenshealth #Libtayo #cemiplimab #NHSScotland #cervicalcancer #immunotherapy #Regeneron #ScottishMedicinesConsortium #SMCacceptance #SMC #metastaticcervicalcancer #humanmonoclonalantibody #immunecheckpointreceptor #EMPOWERCervical1phase3trial
pharmatimes.com/news/libtayo...